Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the ...

Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of ...

Completed the acquisition of lead management portfolio of medical devices and certain related assets from Cook Medical Holdings, LLC; Announced FDA premarket approval of the Wraps ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and ...

Given that the understanding around proteinuria as a potential full approval endpoint is new, Leerink analysts said it would not be surprising if the FDA wanted to discuss the results during an ...

Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies.